Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill For Cannabinoid Therapies

Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies

ISRAEL: Intec Pharma, a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced the results from a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with cannabidiol (CBD) and tetrahydrocannabinol (THC), the two primary cannabinoids contained in Cannabis sativa. “We’re excited about these encouraging results from our Read the full article…

Tilray Announces Support For Clinical Trial Examining Cannabis And Chronic Lung Disease

Tilray clinical trials progress

CANADA: Tilray, a global leader in medical cannabis research and production, today announced a partnership with the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, one of the world’s premier public academic and research institutions, to study the effects of vaporized cannabis on symptoms associated with chronic obstructive pulmonary disease (COPD). The Phase II trial will Read the full article…

Review Identifies 140 Controlled Clinical Trials Related to Cannabis

mmj

GERMANY: Scientists have conducted over 140 controlled clinical trials since 1975 assessing the safety and efficacy of either whole-plant cannabis or specific cannabinoids, according to a literature review published in the journal Critical Reviews in Plant Sciences. A pair of German researchers identified 140 clinical trials involving an estimated 8,000 participants. Of these, the largest body of literature focuses Read the full article…

Medical Marijuana NY-Based Biotech Company Enters Clinical Trials

Controlled-release hemp oil CBD chewing gum and matching placebo gums will be tested for the clinical studies

NEW YORK:  AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus cannabidiol (CBD) gum at Wageningen University in the Netherlands. Human Clinical Trials Detail Include: Controlled-release hemp oil CBD chewing gum and matching placebo gums will be tested for the Read the full article…

The Arthritis Society Canada Funds More Medical Cannabis Research Amid Legalization Speculation

the-arthritis-society

New clinical trial will study use of oral cannabinoids for fibromyalgia pain CANADA: The Arthritis Society has announced the winner of its latest research grant for the study of medical cannabis and arthritis. McGill University’s Dr. Mark Ware, who has garnered a worldwide reputation as a leader in pain research, will lead a trial examining the Read the full article…

7 Things You Need To Know About Sativex

Recognizing their medical capacity, major pharmaceutical companies have put to use derivatives of the chemicals found in marijuana or their synthetic counterparts to address various ailments.

GREAT BRITAIN: Many are starting to hear about a marijuana-based pharmaceutical called Sativex. The drug, which comes as an oral spray, has already been approved in 24 countries as a treatment for multiple sclerosis. While yet to be approved in the United States, Sativex is legally available in countries like Canada, Australia, Britain and, most recently, Read the full article…

FDA-Approved Medical Marijuana Clinical Trial Gets Underway Next Month For Kids With Epilepsy

Meghan Wilson holds the marijuana they just obtained as her husband Brian gets their 2 year old daughter Vivian ready to go outside the Compassionate Care Foundation, New Jersey's 2nd medical marijuana dispensary.

NEW JERSEY: A nationally renowned pediatric neurologist at Saint Barnabas has gotten FDA approval to study whether a cannabis-based drug could prevent seizures in children diagnosed with severe forms of epilepsy. The development is sure to be watched closely in New Jersey, where a number of families whose children have Dravet syndrome, a potentially deadly form Read the full article…